Potentially hazardous drug–drug interactions in cancer patients treated
with tyrosine kinase inhibitors: A multicenter retrospective study
Aims: Tyrosine kinase inhibitors (TKIs) improve patient
outcomes, but the prevalence of clinically significant TKI-associated
drug–drug interaction (DDI) is unknown. We aim to assess the risk
prevalence between TKIs and other drugs in cancer patients.
Methods: This was a retrospective cross-sectional study
conducted in three tertiary care hospitals. All medical data were
collected in the computer-based medication prescription system from
January 2020 to December 2020. The hazardous DDIs identification has
been performed using US Food and Drug Administration-approved labels.
Descriptive statistics and univariate and multivariate logistic
regression analyses were applied to identify risk factors associated
with potential hazardous interactions. Results: A total of 2754
patients were included in our study. 413 hazardous DDIs were identified
and 387 (14.1%) patients experienced at least one DDI. Proton pump
inhibitor, dexamethasone and fluoroquinolones were most frequently
implicated in clinically relevant DDIs with TKIs. In a multivariate
analysis, younger age, the number of drugs and lung cancer had a higher
risk for the occurrence of hazardous DDIs. Conclusions: The
prevalence of hazardous DDIs is relatively high in the cancer patient
population receiving TKIs treatment. The awareness of potential
clinically relevant DDIs can help patients reduce the probability of
adverse event of drugs.